The Allergy Epidemic - Why Are So Many of Us Reacting to the World?
The Allergy Epidemic: Why Are So Many of Us Reacting to the World?
Allergic disease is one of the fastest-growing chronic health challenges of our time. From food allergies to hay fever, asthma to eczema, rates have surged over the past half-century - and scientists are only beginning to understand why. Microplastics, vanishing biodiversity, and a warming planet are all emerging suspects in what is increasingly being described as a global epidemic.
The Scale of the Problem
The numbers are stark. Allergic diseases now affect somewhere between 10% and 40% of the population in most developed countries, depending on the condition and region measured. In Europe, allergy is the most common chronic disease. More than 150 million Europeans suffer from chronic allergic conditions, and projections have long suggested that by 2025, half the entire EU population could be affected in some form.
Food allergy alone tells a striking story. In the United States, prevalence has increased by 50% since the 1990s, with around 6.2% of adults and 5.8% of children now affected. Approximately 25.7% of U.S. adults report seasonal allergies. In the UK, hospital admissions for severe allergic reactions were seven times higher in 2015 than they were just a decade earlier, in 2005. The incidence of atopic eczema has increased two to threefold in industrialised countries over the past three decades, now affecting 15–30% of children and up to 10% of adults at some point in their lives.
These are not marginal shifts. Something in the modern environment is profoundly disturbing the human immune system - and researchers are converging on several intertwined explanations.
The Hygiene Hypothesis and Its Evolution
For decades, the leading framework for understanding the allergy rise has been the “hygiene hypothesis,” first proposed by epidemiologist David Strachan in 1989. Strachan noticed that in a survey of more than 17,000 British children, those born into larger households - where infections were shared more readily among siblings - were less susceptible to eczema and hay fever. His interpretation: early childhood exposure to infectious agents primes the immune system, reducing the risk of overreaction to benign substances like pollen or peanuts.
The core insight proved durable. Since the 1950s, rates of asthma, multiple sclerosis, Crohn’s disease, type 1 diabetes, and allergic conditions have soared by 300% or more in developed nations - running in near-perfect parallel with sharp declines in childhood infections, driven by vaccines, antibiotics, and improved sanitation.
Yet the hygiene hypothesis has also been widely misunderstood and misapplied. Scientists now caution that it has become a “dangerous misnomer” that implies we should embrace dirt and abandon personal cleanliness. The truth is far more nuanced. What appears to matter is not hygiene in the household sense, but the loss of specific microbial exposures that evolved alongside the human immune system for millennia - in soil, in water, in fermented food, and through contact with animals and natural environments.
This has given rise to a more sophisticated successor framework: the biodiversity hypothesis.
The Biodiversity Hypothesis: When Urban Life Starves the Immune System
According to the biodiversity hypothesis, reduced contact with natural environments and the microorganisms that inhabit them disrupts the composition of human skin and gut microbiota, impairing the immune system’s ability to regulate itself. Research has shown that atopic individuals - those prone to allergic conditions - have measurably lower environmental biodiversity in the surroundings of their homes, and significantly lower diversity of certain bacterial classes on their skin compared to healthy individuals.
The implications are sobering: by 2050, two-thirds of the global human population is projected to live in urban areas with limited contact with nature and biodiversity. As urbanisation accelerates, exposure to diverse microbial ecosystems shrinks. The gut and skin microbiomes, shaped by millions of years of co-evolution with environmental microorganisms, become impoverished - a state scientists call dysbiosis. The result is an immune system that struggles to distinguish genuine threats from harmless ones, and so overreacts to both.
This picture is further complicated by diet. A western diet poor in fresh fruit and vegetables may act in synergy with dysbiosis of the gut flora, further tilting the immune system toward inflammation and allergic sensitisation. Physical inactivity compounds the problem.
Climate change adds another layer. Rising CO₂ levels have been shown to dramatically increase pollen production - one study found a 132% increase in ragweed pollen comparing pre-industrial to current CO₂ levels, with a projected additional 90% increase by 2100. Warmer temperatures are extending pollen seasons, with some species showing season extensions of over 80 days. Longer, more intense pollen seasons mean longer and more intense allergic responses - even for those who have long managed their symptoms.
Enter Microplastics: A New Suspect
Perhaps the most alarming recent development in allergy research is the emerging evidence linking microplastics to allergic disease. Once considered a concern primarily for marine ecosystems, microplastics are now understood to be ubiquitous in the human body - detectable in blood, lungs, gut, breast milk, and even the placenta.
Microplastics enter the body through three main pathways: inhalation of airborne particles, ingestion through food and water, and to a lesser extent dermal contact. Of these, researchers are increasingly concerned that inhalation poses the greatest risk, because what is breathed deep into the lungs cannot be easily expelled the way ingested particles can pass through the digestive system.
A 2025 study published in Environmental Geochemistry and Health confirmed that microplastics can be detected in the respiratory tract and lungs, and that prolonged exposure disrupts airway epithelial cell metabolism and compromises epithelial barrier integrity - making the airway highly reactive. A separate study found that microplastic density in nasal lavage fluid was significantly higher in rhinitis patients - both allergic and non-allergic - than in healthy controls, with higher concentrations strongly predicting the likelihood of sneezing. Notably, younger people showed higher microplastic loads, a finding with troubling implications for future generations.
The central mechanism appears to involve what researchers describe as epithelial barrier disruption. The epithelial barrier - the thin layer of cells lining our skin, airways, and gut - is the body’s first line of defence against the outside world. When this barrier is compromised, allergens can penetrate more deeply into tissues, triggering sensitisation and inflammation. Microplastics appear to do exactly this. A 2025 review in the International Archives of Allergy and Immunology concluded that microplastic particles compromise epithelial barriers and promote a specific type of immune response - known as Th2 polarisation and type 2 inflammation - that is the hallmark of allergic disease.
Beyond direct barrier damage, microplastics provoke immune disturbances through the release of inflammatory signalling molecules called alarmins, and through oxidative stress - cellular damage caused by unstable chemical reactions. There is also epidemiological correlation between microplastic exposure and increased incidence and severity of asthma, allergic rhinitis, and atopic dermatitis.
Research into food allergy adds another dimension. Microplastics may bind to food allergens in the gut, altering their chemical structure in ways that make them more provocative to the immune system. They may also reduce the gut’s ability to digest allergens normally, increase intestinal permeability - the so-called “leaky gut” effect - and promote intestinal inflammation and dysbiosis. All of these factors could plausibly heighten sensitisation to food proteins. Studies examining pregnant women have found associations between phthalate metabolites in urine - phthalates being chemical additives used to soften plastics - and increased asthma risk in their children, with the effect replicated in animal models.
The EU-funded IMPTOX research project, which presented preliminary findings in Brussels in February 2025, is among several major initiatives now dedicated specifically to investigating whether micro- and nanoplastics are fuelling the allergy epidemic. The scientific consensus remains cautious - researchers stress that more is not yet known than is known - but the direction of evidence is increasingly concerning.
A Convergence of Causes
What emerges from the research is not a single villain, but a constellation of forces acting together on a human immune system that evolved under conditions vastly different from the modern world:
Loss of microbial diversity, driven by urbanisation, antibiotic use, caesarean births, formula feeding, and the disappearance of farm-based lifestyles, leaves immune systems under-stimulated and prone to misdirected responses.
Climate change is lengthening pollen seasons, intensifying extreme weather events that concentrate allergens and pollutants, and expanding the geographic range of allergenic species.
Chemical pollution - from pesticides, detergents, synthetic fragrances, and plastic additives like phthalates and bisphenols - compounds the damage to epithelial barriers and the microbiome.
Microplastics now permeate every environment humans inhabit and every food system they depend on, introducing a novel form of chronic immune provocation unlike anything the human body has encountered before.
Diet and lifestyle changes in Western societies, including ultra-processed foods, lower fibre intake, and reduced outdoor activity, further erode the microbial and immunological resilience that once kept allergies in check.
The Future Outlook
The trajectory, absent significant intervention, is troubling. Allergy specialists forecast continued increases in prevalence, severity, and the range of allergens to which populations are sensitised. The economic burden is already vast - the annual cost of atopic dermatitis alone in the United States is estimated at over $5 billion.
There are, however, grounds for cautious optimism. The science of immunotherapy - desensitising patients to allergens through carefully controlled exposure - is advancing rapidly, and new biological treatments targeting the specific inflammatory pathways involved in allergic disease are transforming outcomes for many patients. Early-life dietary interventions, such as the deliberate introduction of potential food allergens like peanuts in infancy, have shown real promise in reducing sensitisation rates.
On a broader scale, growing recognition of the microbiome’s role in immune health is beginning to shift thinking about early childhood environments, childbirth practices, and the value of exposure to nature and diverse microbial ecosystems. Urban planning that incorporates green space and biodiversity is increasingly understood as a public health issue, not merely an aesthetic one.
The challenge of microplastics, however, may prove harder to address. Plastic pollution is now so deeply embedded in global supply chains, food systems, and atmospheric circulation that reducing human exposure requires systemic change on a civilisational scale. Regulatory pressure is building, and a global plastics treaty has been under negotiation - but progress remains slow relative to the pace at which these particles are accumulating in human tissue.
What the science makes increasingly clear is that the allergy epidemic is not a quirk of individual biology or bad luck. It is a signal - the immune system’s response to a world that has changed faster than evolution can follow. Understanding that signal, and acting on it, is one of the defining public health challenges of the twenty-first century.
Sources include research published in the International Archives of Allergy and Immunology, Environmental Geochemistry and Health, ScienceDirect, PNAS, the World Allergy Organization Journal, and findings from the EU-funded IMPTOX and CUSP research consortia.